Second-generation travoprost intracameral implant shows “impressive” results in IOP lowering
Steve Sarkisian, MD, of Oklahoma Eye Surgeons, presented an ongoing study at the AGS 2026 Annual Meeting assessing the second-generation iDose TREX, a sustained-release travoprost intracameral implant. So far, the results have shown “impressive” intraocular pressure (IOP) lowering in the first 10 patients.
Steve Sarkisian, MD:
Hi. I’m Steve Sarkisian, Founder and CEO of Oklahoma Eye Surgeons in Oklahoma City. At the AGS Meeting 2026 at Rancho Mirage, California, I was able to present some data about the [iDose] TREX, which is a sustained-release travoprost. It is the second generation from Glaukos of sustained-release travoprost. It’s not a MIGS, the procedural pharmaceutical, it’s an implant that gets placed in the anterior chamber, it’s anchored there, and it releases medicine. Now, the canister has twice the capacity of the iDose TR. What we’re going to be studying is not only the efficacy, but the length of efficacy because the study is going to be a 3-year study, much like the iDose TR study was. But we have the first 10 patients that we’ve done, and my colleagues and I have presented at the AGS Meeting and the baseline IOP, basically it was 10 patients, it was non-randomized, and it was 10 subjects enrolled.
Unmedicated mean diurnal IOP was 24.3 mmHg at baseline. Even at day 11, the IOP dropped by 44%, 10.8 mmHg. Then at 6 weeks, we saw maintained pressure at 37% with IOP having dropped by 9.4 mmHg. Impressive results so far.
Just a word about the iDose platform in general, in that, again, it’s a procedural pharmaceutical, 24/7 IOP-lowering. We have 2 very robust randomized clinical trials that I was blessed to be a part of with really good data having been published and after several hundred of these, of the iDose TR, we’ve had amazing results and we’ve really been changing the face of how glaucoma has been treated. Excited to be able to present the next generation, the iDose TREX at the AGS Meeting in 2026.
Related Content
